Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

Erimos Pharmaceuticals LLC manufactures drugs. It is a biopharmaceutical company focused primarily on the discovery, development and commercialization of small molecule drugs to prevent and treat cancer. The firm��s pre-clinical programs are underway to create advancements in treating other serious medical conditions including influenza, Alzheimer��s disease, diabetes, psoriasis, obesity, and infectious disease. The company was founded by Franklin C. Jesse Jr. and Jeffrey Khoo in 2000 and is headquartered in Houston, TX.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company was founded by Peter Laurence Molloy and Stephen Goodall on April 12, 2012 and is headquartered in Melbourne, Australia.

Shenghua (Guangzhou) Pharmaceutical Technology Co., Ltd., established on 2005-09-26, The scope of business includes the manufacture of daily chemical products;Intellectual Property Services;Production of protective equipment for medical personnel(Ι class medical device);Production of Class I Medical Devices;daily mask(non-medical)Production;Wholesale of protective equipment for medical staff;daily mask(non-medical)Sales;Disinfectant sales(Free of Hazardous Chemicals);Sales of hygiene products and single-use medical products;Daily necessities sales;Daily necessities wholesale;Maternal and baby products sales;internet sales(Except for products that require a license for sale);Chinese herbal medicine acquisition;Personal Hygiene Sales;Cosmetics Wholesale;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Chemical product sales(No licensed chemical products);Wholesale medical masks;Sales of daily chemical products;Medical Mask Retail;Retailing of protective equipment for healthcare workers;Adult Sex Toys Sales(Does not contain drugs,medical instruments);Cosmetics Retail;Remote Health Management Services;Medical Research and Experimental Development;Extraction of marine bioactive substances,purification,Synthesis technology research and development;R&D and application of cell technology;Biochemical product technology research and development;Science popularization service;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Health Consulting Services(Does not include medical services);Nursing facility services(Does not include medical services);Maternal and infant life care(Does not include medical services);Rehabilitation assistive device fitting service;Advertising Design,acting;trade broker;sales agent;Information Consulting Service(Not including licensing information consulting services);Socioeconomic Advisory Services;software development;Information Technology Consulting Services;Internet of Things Technology Services;Sports Health Service;

ARCH Development Corp., part of The University of Chicago, is an American company that provides job training and housing development services. Duane Gautier is currently the CEO of the firm.

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).

Provides financial and employee benefits services

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

Part of University of Arkansas System, Board of Trustees of The University of Arkansas is a company headquartered in Fayetteville, AR, that owns and operates radio stations.

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

Bioventures LLC is an American private company located in Tulsa, OK, that develops pharmaceutical products. The firm was founded in 2004.

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Myriad Genetics, Inc. is an American molecular diagnostic company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to a particular drug therapy (personalized medicine), assess a patient's risk of disease progression and disease recurrence (personalized medicine), and measure disease activity. Myriad's discovery of the breast cancer gene, BRCA1 was universally acclaimed as a monumental achievement: "There is no more exciting story in medical science." Myriad was the subject of scrutiny after it became involved in a lawsuit over its patenting practices, which led to the landmark Supreme Court decision Association for Molecular Pathology v. Myriad Genetics, Inc..

Squarex is a clinical-stage pharmaceutical company developing a drug and topical application to prevent infections. This application develops a topical formulation of the immunomodulator squaric acid dibutyl ester for the prevention of recurrent cold sores and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2. The company was founded in 2012 and is headquartered in Saint Paul, Minnesota.

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

American Cyanamid Company was a U.S.-based diversified company with businesses in several fields. The company was a manufacturer of agricultural chemicals, cosmetics, perfumes, building products, plastics and pharmaceuticals. The company was listed as a top 100 manufacturing company by Fortune magazine in the 1970s. Cyanamid was founded in 1907 and employed over 100,000 people around the world by 2000. The company maintained a monopoly over tetracycline, an antibiotic used against bacterial infections. A theft of the organism led to the loss of the monopoly as rival companies were able to produce generic versions of the formula, leading to huge losses to the company. The company sold most of its businesses in the early 2000s and is now operated under the name Cytec.  

MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.